Ligand Development Program
The development of new radioligands by GE Healthcare involves a rigorous process of testing and optimization. Wherever possible, the radiolabeled compound is validated in a receptor binding assay before a product is made routinely available. This testing is frequently carried out by partners and collaborators.
The ligands included on this page are just some of the products which GE Healthcare is currently developing. If you would like to participate in the Ligand Development Program and obtain samples of any of these compounds or have suggestions for other ligands to be radiolabeled, please contact your local representative.
| Radioligand : | [125I]Ghrelin |
| Classification : | GHS-R |
| Reference/comments : | Kojima et al., Nature, 402, pp.656-660, 1999 |
 | |
| Radioligand : | [125I]Neuropeptide FF |
| Classification : | NFPP |
| Reference/comments : | Minault, M., et al., Peptides, 16 (1), pp105-111, 1995 |
| |
| Radioligand : | [125I] CART (55-102), human |
| Classification : | Endogenous |
| Reference/comments : | Thim,L., et al., Febs Letters, 428, pp263-268, 1998 |
| |
| Radioligand : | [125I]viral MIP-II |
| Classification : | US28 agonist |
| Reference/comments : | High affinity binding – personnal communication 1999 |
|
Note - GE Healthcare makes no guarantee about the performance or availability of these samples. Labeling of these ligands is still developmental and consequently batches may differ in labelling technique or formulation until marketed as a catalog product. Discussion of ligand performance with our radiochemists is encouraged in order to generate the optimum product for your individual assays.
| 
